GILEAD SCIENCES, INC. (GILD) FY2024 Q3 P&L / Income Statement

GILEAD SCIENCES, INC. (GILD) FY2024 Q3 P&L / Income Statement

Income statement for 2024-07-01 through 2024-09-30. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

7,545,000,000 US dollars

Cost of goods sold

1,574,000,000 US dollars

Gross profit (calculated)

5,971,000,000 US dollars

Operating expenses (calculated)

5,083,000,000 US dollars

Operating income (loss)

888,000,000 US dollars

Other income (expense), net (calculated)

68,000,000 US dollars

Income (loss) before income taxes

956,000,000 US dollars

Income tax (benefit) expense

negative 297,000,000 US dollars

Net income (loss)

1,253,000,000 US dollars

Tecartus

98,000,000 US dollars

Yescarta

387,000,000 US dollars

Biktarvy

3,472,000,000 US dollars

Descovy

586,000,000 US dollars

Genvoya

449,000,000 US dollars

Odefsey

326,000,000 US dollars

Symtuza - Revenue share

139,000,000 US dollars

Other HIV

100,000,000 US dollars

Sofosbuvir/Velpatasvir

385,000,000 US dollars

Vemlidy

232,000,000 US dollars

Other Liver Disease

116,000,000 US dollars

Trodelvy

332,000,000 US dollars

AmBisome

130,000,000 US dollars

Other

71,000,000 US dollars

Royalty, contract and other revenues

30,000,000 US dollars

Veklury

692,000,000 US dollars

Selling, general and administrative expenses

1,433,000,000 US dollars

Acquired in-process research and development expenses

505,000,000 US dollars

Research and development expenses

1,395,000,000 US dollars

In-process research and development impairment

1,750,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.